Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study by Søltoft Larsen, Kasper et al.
Syddansk Universitet
Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested
Case-Control Study
Larsen, Kasper Søltoft; Pottegård, A; Lindegaard, Hanne Merete; Hallas, Jesper
Published in:
P L o S One
DOI:
10.1371/journal.pone.0146172
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Søltoft Larsen, K., Pottegård, A., Lindegaard, H. M., & Hallas, J. (2016). Impact of Urate Level on Cardiovascular
Risk in Allopurinol Treated Patients. A Nested Case-Control Study. P L o S One, 11(1), 1-13. [e0146172]. DOI:
10.1371/journal.pone.0146172
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
RESEARCH ARTICLE
Impact of Urate Level on Cardiovascular Risk
in Allopurinol Treated Patients. A Nested
Case-Control Study
Kasper Søltoft Larsen1,3*, Anton Pottegård1, Hanne M. Lindegaard3, Jesper Hallas1,2
1 Clinical Pharmacology, Department of Public Health, University of Southern Denmark, JBWinsloewvej
19.2, DK-5000, Odense C, Denmark, 2 Department of Clinical Chemistry & Pharmacology, Odense
University Hospital, JB Winsloewvej 19.2, DK-5000, Odense C, Denmark, 3 Department of Rheumatology,
Odense University Hospital, Sdr. Boulevard 29, DK-5000, Odense C, Denmark
* kaslarsen@health.sdu.dk
Abstract
Background
Gout gives rise to increased risk of cardiovascular events. Gout attacks can be effectively
prevented with urate lowering drugs, and allopurinol potentially reduces cardiovascular risk.
What target level of urate is required to reduce cardiovascular risk is not known.
Objectives
To investigate the effect of achieving target plasma urate with allopurinol on cardiovascular
outcomes in a case-control study nested within long-term users of allopurinol.
Methods
We identified long-term users of allopurinol in Funen County, Denmark. Among these, we
identified all cases of cardiovascular events and sampled 4 controls to each case from the
same population. The cases and controls were compared with respect to whether they
reached a urate target below 0.36 mmol/l on allopurinol. The derived odds ratios were con-
trolled for potential confounders available from data on prescriptions, laboratory values and
in- and outpatient contacts.
Results
No association between treatment-to-target urate level and cardiovascular events were
found (adjusted odds ratio of 1.01, 95% confidence interval 0.79–1.28). No significant effect
was seen in any subgroup defined by age, gender, renal function, allopurinol dose or the
achieved urate level. Overall, the doses of allopurinol used in this study were low (mean 
140 mg/day).
Conclusion
We were unable to demonstrate a link between achieved urate level in patients treated with
allopurinol and risk of cardiovascular events. Possible explanations include that allopurinol
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doses higher than those used in this study are required to achieve cardiovascular risk
reduction or that the cardiovascular effect of allopurinol is not mediated through low urate
levels. It remains to be seen whether allopurinol has a dose-response relationship with car-
diovascular events at higher doses.
Introduction
Gout is the most prevalent inflammatory arthritis, affecting up to 4% of the population in
developed countries [1]. Gout attacks can be effectively prevented by use of urate lowering
therapy (ULT) [2], such as allopurinol. The aim of ULT is to prevent future attacks of gouty
arthritis primarily by decreasing plasma urate level to below 0.36 mmol/l (6.0 mg/dl), which is
below the precipitation point of urate at physiological conditions [3].
Allopurinol is the most widely used ULT. In addition to its urate lowering properties, allo-
purinol has been shown to reduce blood pressure among patients with hypertension [4],
increase work capacity in chronic stable angina patients [5], diminish vascular oxidative stress
and endothelial dysfunction [6,7]. In addition, allopurinol 300 mg daily or higher has recently
been associated with improved cardiovascular outcome [8].
However, the above-mentioned effects on hypertension and work capacity has only been
shown with very high doses (> 400 mg/day and> 600 mg/day respectively) [4,5].
The treat-to-target approach (urate level below 0.36 mmol/l) with ULT is developed for
gout related symptoms, but whether this approach is also sufficient to achieve a reduction in
cardiovascular risk remains to be established. We sought to investigate the effect of achieving
target plasma urate with allopurinol on cardiovascular outcomes in a case-control study nested
within long-term users of allopurinol.
Methods
This case-control study nested among long-term users of allopurinol was carried out in Funen
County, Denmark, using health care registries furnished by the Danish health authorities.
Cases were defined by an Antiplatelet Trialist’s collaboration (APTC) cardiovascular endpoint
and controls were without the APTC endpoint. We ascertained whether individuals had
achieved target urate level and analyzed the association between in-target urate level and risk
of the APTC endpoint.
Data sources
We linked data from the following four health care registries:
1. The laboratory database of Odense University Hospital is a clinical laboratorial system,
which contains information on all blood samples analyzed at every hospital laboratories in
the Funen County since November 1992. The coverage includes primary and secondary
health care providers for both in- and outpatients. All urate measurements measured at
inhabitants in the Funen County during the study period were covered.
2. The Odense University Pharmaco-epidemiological Database (OPED) is a prescription data-
base holding information on redeemed, reimbursed prescriptions for the citizens of Funen
County since 1990 [9]. Data included are a full account of the dispensed product and the
date of dispensing. The product is described in terms of the defined daily dose (DDD) and
the anatomical-therapeutic-chemical (ATC) code [10]. OPED includes a demographic
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module with information on residency, migration, births and death, which allowed us to
account for censoring.
3. The Funen County Patient Administrative System provides hospital discharge diagnosis for
the population of Funen County since 1977 for inpatients and since 1989 for outpatients.
The diagnoses are encoded according to the International Classification of Diseases 8th revi-
sion (ICD8) until January 1994 and ICD10 thereafter.
4. The Danish Register of Causes of Death holds information on all causes of death among
Danish citizens, encoded according to the ICD classification system. The National Board of
Health established the current register in 1875 [11].
The Record linkage was made possible by a unique personal identifier, assigned to all Dan-
ish citizens since 1968 [12]. In Denmark public health authorities provide virtually all health
services, which allows true population based epidemiological studies [13].
Cases and controls
Source population. The population used in this setting was derived from the total popula-
tion from Funen, Denmark ( 485,000), during the period of December 1992 through Decem-
ber 2010. Among these we identified first-ever users of allopurinol (ATCM04AA01) with an
elevated ( 0.36 mmol/l) urate measurement within 2 years prior to their first allopurinol pre-
scription (9,118 individuals) (Fig 1). From this basic cohort basic cohort of hyperuricemic allo-
purinol users both cases and control were selected.
Cases. Cases were identified as individuals developing their first APTC event [14] during
follow-up, using the day of this event as the index date. In brief, the APTC endpoint is a non-
fatal myocardial infarction (MI) (ICD8 410; ICD10 I21-I22), a non-fatal stroke (ICD8 430–
434; ICD10 I60-I64), or cardiovascular death (ICD8 390–458; ICD10 I00-I99) including
unknown causes of death (ICD8 780–796; ICD10 R96-R99).
In addition, we applied the following inclusion criteria prior to the index date:
1. At least 18 years of age.
2. Living in Funen at the index date and for the past five years (individuals who migrated
inside this period were excluded, see Fig 1.).
3. Cancer free for 5 year, defined by the absence of any of the following diagnosis of malignan-
cies (ICD8 140–207; ICD10 C00-C96), not including non-melanoma skin cancer (ICD8
173; ICD10 C44).
4. No treatment with other ULT than allopurinol.
5. Continuous use of allopurinol in the year preceding the index date. Defined as follows; an
individual was considered an allopurinol user if she or he had redeemed prescriptions for
allopurinol that added together would cover the index date and the entire year preceding
the index date. For each prescription, we assigned a period of usage starting on the date of
the prescription and lasting a number of days corresponding to the number of tablets, thus
assuming an average daily intake of one tablet. In order to allow for non-compliance and
irregular prescription renewals we added a grace period (a period of time in which non-
redeeming of allopurinol prescriptions was allowed) of 180 days to the usage period
assigned to each prescription of allopurinol. The usage clock was reset at each new
prescription.
For numbers of cases excluded in each step and final number of cases see Fig 1.
Urate Level and Cardiovascular Risk
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Controls. Controls were selected randomly based on their availability in the cohort of
hyperuricemic allopurinol users and matched by age and sex using risk set sampling with a
maximum case:control ratio of 1:4. The controls were subjected to the same inclusion criteria
as the cases (except the APTC endpoint). As we had full coverage of death and migrations out
of the county, we could effectively account for all individuals’ presence in the cohort. The con-
trols were assigned an index date identical to the index date of the corresponding case in the
risk set.
Fig 1. Study flow diagram.
doi:10.1371/journal.pone.0146172.g001
Urate Level and Cardiovascular Risk
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Controls were not allowed to have had an APTC endpoint before their selection as controls,
but might have one later and thus be re-selected as cases. By this approach, the odds ratio is an
unbiased estimate of the incidence rate ratio [15].
Not all cases had 4 possible matches, therefore the final case:control ratio differs from 1:4.
The final number of controls and number excluded at each step of inclusion are given in Fig 1.
Urate level
Both cases and controls were classified as either hyperuricemic or treated-to-target. This classi-
fication was based on an average of all urate samples from the time of allopurinol prescription
until the index date (weighted by the number of days spent at each different plasma urate
level). The plasma urate level at any given day was set to the same value as the closest measure-
ment prior to that day. Individuals would be classified as treated-to-target if the weighted urate
level prior to index date were below 0.36 mmol/l.
Analysis
The adjusted odds ratios (ORs) with 95% confidence intervals (CI) were derived using condi-
tional logistic regression with adjustment for potential confounders. Variables known or sus-
pected to influence cardiovascular diseases were included as potential confounders in the
regression model. Current use of other drugs than allopurinol was defined by the redeeming of
a prescription for this particular drug less than 120 days before the index date. Previous diagno-
ses were defined by having an in- or outpatient contact coded with the corresponding ICD8 or
ICD10 code. See S1 Table for further details on included variables.
For missing continuous covariates we used median value imputation and missing dichoto-
mous variables were set to absent. In subgroup analyses defined by covariates with imputed
data, individuals with missing data were excluded.
Baseline characteristics were presented for cases and controls as well as exposed and unex-
posed controls (as a proxy for the source population) [16].
Additional analyses and pre-specified sensitivity analyses
We carried out a range of supplementary analyses. First we used different exposure definitions,
by using different urate cut-off values to define the treat-to-target group (urate< 0.20 mmol/l;
urate< 0.3 mmol/l; urate< 0.36 mmol/l; urate< 0.42 mmol/l; urate< 0.48 mmol/l), and by
grouping individuals according to their decrease in achieved weighted plasma urate relative to
the baseline value.
Subsequently we conducted a number of subgroup analyses. We restricted the analysis by
strata of age, sex and renal function (defined as chronic kidney disease stages by the National
kidney foundation [17]). We also restricted the analysis by only considering individuals with
and without diabetes, hypertension and previous APTC events, in order to estimate the effect
in groups with different risk of the outcome. Further we analyzed subgroups defined by cumu-
lative doses of allopurinol; (<200 g, 200–400 g,> 400 g) and as average daily intake (< 150
mg/d, 150–250 mg/d and> 250 mg/d).
One critical issue in this study is the definition of when an individual is treated-to-target.
First, we performed an analysis were the plasma urate level at any given day was set to the
mean value as the closest measurement prior to and after that day, rather than the first value
alone. Second, we only included urate measurement from the last 1 and 3 years before the
index date to calculate the weighted urate levels. Third, we only considered the latest urate
measurement. Fourth, we omitted urate measurements inside 3 month of the index date; this
analysis was done to check for any biased results caused by urate levels measured in
Urate Level and Cardiovascular Risk
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conjunction with an admission for a case event. Lastly, we changed the grace period for allopu-
rinol prescriptions to 0, 1, 3 and 12 months.
Post hoc we conducted an analysis applying all covariates one by one and in groups (i.e. all
comorbidities, all laboratory values or all prescriptions), because the estimates changed
markedly after adjustment.
Ethics
The project was approved by the Danish Data Protection Agency. Registry based studies do
not require ethical approval in Denmark, nor do it require personal written consent [18]. All
individuals were anonymized prior to retrieval of data and all analyses were performed at
anonymized data.
Results
We identified 538 APTC cases and 1,791 controls with at least one year of continuous allopuri-
nol use. Altogether 1,638 (70.3%) were men and the median age was 78 (IQR; 70–84) years.
The median urate levels decreased markedly after allopurinol treatment start among both cases
and controls—on average a 27.4% decrease was observed. Other characteristics of the APTC
cases and their controls along with exposed and unexposed controls are presented in Table 1.
Treat to target approach
Among cases and controls, 197 (36.6%) and 728 (40.6%) were treated-to-target plasma urate
level below 0.36 mmol/l respectively. The crude and adjusted odds ratios (OR) of APTC events
among individuals treated-to-target urate below 0.36 mmol/l were 0.77 (95% CI 0.62–0.95)
and 1.01 (95% CI 0.79–1.28) (Table 2).
Allopurinol exposure patterns
We found no association of increasing cumulative amounts of allopurinol with respect to
APTC outcomes (Table 2). Similarly, we did not find any association with duration of continu-
ous allopurinol use or with increasing amounts of daily use (Table 2). All tests for trend were
statistically non-significant.
Subgroups
No differences in analysis of different subgroups defined by age, sex or a history of diabetes,
hypertension or cardiovascular disease were found (Table 2).
Urate exposure patterns and cardiovascular events
We found no association between the degree of change in urate level and cardiovascular events.
Changing the urate target to different levels showed an increased risk of APTC events for very
low levels of urate (< 0.20 mmol/l). Results are presented in Table 3.
Sensitivity analyses
Changing the definition of treated-to-target to include only the last urate measurement or the
definition of weighted urate to only include the last 1 and 3 years of urate measurements did
not change the overall results (data not shown). Neither did using the alternative approach to
calculate the weighted urate levels. Changing the grace periods did not alter the main results,
Urate Level and Cardiovascular Risk
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Table 1. Characteristics of APTC cases and their corresponding controls, and for unexposed and exposed controls (proxy for distribution in the
source population).
Cases
(n = 538)
Controls
(n = 1,791)
Unexposed Controls
(n = 1,063)
Exposed Controls
(n = 728)
Men 365 (67.8%) 1,273 (71.1%) 815 (76.7%) 458 (62.9%)
Women 173 (32.2%) 518 (28.9%) 248 (23.3%) 270 (37.1%)
Age, median (IQR) 79 (71–86) 77 (70–84) 77 (70–83) 78 (71–85)
History of:
Ischemic heart disease 284 (52.8%) 589 (32.9%) 390 (36.7%) 199 (27.3%)
Heart failure 241 (44.8%) 393 (21.9%) 271 (25.5%) 122 (16.8%)
Atrial ﬁbrillation 176 (32.7%) 363 (20.3%) 264 (24.8%) 99 (13.6%)
Stroke 101 (18.8%) 249 (13.9%) 158 (14.9%) 91 (12.5%)
Diabetes mellitus 128 (23.8%) 274 (15.3%) 176 (16.6%) 98 (13.5%)
Hypertension 221 (41.1%) 532 (29.7%) 339 (31.9%) 193 (26.5%)
COPD 92 (17.1%) 180 (10.1%) 121 (11.4%) 59 (8.1%)
Charlson comorbidity index:
0 70 (13.0%) 706 (39.4%) 392 (36.9%) 314 (43.1%)
1 140 (26.0%) 440 (24.6%) 248 (23.3%) 192 (26.4%)
2 105 (19.5%) 266 (14.9%) 166 (15.6%) 100 (13.7%)
3 223 (41.4%) 379 (21.2%) 257 (24.2%) 122 (16.8%)
Current drug use (baseline):
Diabetes-drugs (ever use) 87 (16.2%) 259 (14.5%) 168 (15.8%) 91 (12.5%)
Vitamin K antagonists 71 (13.2%) 206 (11.5%) 166 (15.6%) 40 (5.5%)
ADP-receptor inhibitors 9 (1.7%) 20 (1.1%) 14 (1.3%) 6 (0.8%)
Low-dose ASA 177 (32.9%) 457 (25.5%) 269 (25.3%) 188 (25.8%)
Dipyridamole 37 (6.9%) 86 (4.8%) 45 (4.2%) 41 (5.6%)
Heart glycosides 155 (28.8%) 288 (16.1%) 203 (19.1%) 85 (11.7%)
Nitrate vasodilators 128 (23.8%) 207 (11.6%) 112 (10.5%) 95 (13.0%)
Thiazide diuretics 80 (14.9%) 223 (12.5%) 142 (13.4%) 81 (11.1%)
Loop diuretics 330 (61.3%) 748 (41.8%) 463 (43.6%) 285 (39.1%)
Aldosterone antagonists 99 (18.4%) 172 (9.6%) 124 (11.7%) 48 (6.6%)
Betablockers 159 (29.6%) 506 (28.3%) 332 (31.2%) 174 (23.9%)
Calcium antagonists 128 (23.8%) 426 (23.8%) 243 (22.9%) 183 (25.1%)
RAAS blockers 248 (46.1%) 746 (41.7%) 454 (42.7%) 292 (40.1%)
Statins 114 (21.2%) 451 (25.2%) 292 (27.5%) 159 (21.8%)
COPD related drug use 76 (14.1%) 229 (12.8%) 148 (13.9%) 81 (11.1%)
Systemic corticosteroids 70 (13.0%) 116 (6.5%) 71 (6.7%) 45 (6.2%)
NSAIDs 111 (20.6%) 387 (21.6%) 228 (21.4%) 159 (21.8%)
Blood measurements (baseline):
Urate level prior to allopurinol, median
(IQR)
0.55 (0.49–
0.64)
0.52 (0.46–0.60) 0.54 (0.49–0.62) 0.49 (0.43–0.55)
Weighted urate level, median (IQR) 0.39 (0.33–
0.47)
0.38 (0.32–0.43) 0.42 (0.39–0.47) 0.31 (0.27–0.34)
Urate < 0.36 mmol/l (treated to target) 197 (36.6%) 728 (40.6%) 0 (0.0%) 728 (100.0%)
eGFR, median (IQR) 43 (31–58) 52 (40–67) 50 (38–65) 55 (43–69)
High HbA1c (> 6.5%) 82 (15.2%) 212 (11.8%) 140 (13.2%) 72 (9.9%)
High cholesterol (> 5 mmol/l) 115 (21.4%) 329 (18.4%) 215 (20.2%) 114 (15.7%)
Proteinuria 40 (7.4%) 61 (3.4%) 49 (4.6%) 12 (1.6%)
IQR = interquartile range; IHD = ischemic heart disease; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; ASA = acetylsalicylic
acid; ADP = adenosinediphosphat; VKA = vitamin-K-antagonists; RAAS = renin-angiotensin-aldosterone-receptor; NSAID = non-steroidal anti-
inﬂammatory drugs; eGFR = estimated glomerular ﬁltration rate; HbA1c = hemoglobin A1c
doi:10.1371/journal.pone.0146172.t001
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even though there was a non-statistically significant association with lower ORs for the primary
endpoint as the grace periods decreased (S2 Table).
The analyses including potential confounders one at a time showed that no single dominat-
ing covariate or group of covariates was responsible for the heavy adjustment (S3 Table).
Discussion
We found no association between treated-to-target urate level and cardiovascular events
among long-term (> one year) allopurinol treated individuals. Extensive supplementary analy-
ses failed to identify subgroups or exposure patterns that were plausibly related to a reduced
risk of the APTC outcome.
Table 2. Odds ratios for APTC event of treated-to-target for different subgroups.
Exposure pattern Cases In target / Not in
target
Controls In target / Not in
target
Crude OR (95%
CI)
Adjusted* OR (95%
CI)
All users 197 / 341 728 / 1063 0.77 (0.62–0.95) 1.01 (0.79–1.28)
Sex
Men 119 / 246 458 / 815 0.81 (0.62–1.04) 1.03 (0.77–1.38)
Women 78 / 95 270 / 248 0.68 (0.47–1.00) 0.97 (0.62–1.53)
Age groups
Age < 60 years 8 / 32 49 / 99 0.41 (0.16–1.08) 0.45 (0.09–2.36)
Age 60–79 years 86 / 155 356 / 535 0.80 (0.59–1.08) 0.98 (0.69–1.41)
Age  80 years 103 / 154 323 / 429 0.79 (0.57–1.08) 1.10 (0.76–1.59)
Comorbidities
Diabetes 44 / 103 141 / 228 0.88 (0.48–1.60) 1.64 (0.47–5.77)
No diabetes 153 / 238 587 / 835 0.88 (0.68–1.14) 1.12 (0.84–1.50)
Hypertension 70 / 151 193 / 339 0.72 (0.45–1.14) 0.99 (0.56–1.72)
No hypertension 127 / 190 535 / 724 0.82 (0.61–1.10) 1.08 (0.75–1.55)
Previous APTC 52 / 106 129 / 232 1.00 (0.53–1.89) 1.11 (0.39–3.15)
No previous APTC 145 / 235 599 / 831 0.75 (0.58–0.96) 0.95 (0.70–1.29)
Renal function
eGFR > 60 ml / min 48 / 71 290 / 366 0.94 (0.54–1.63) 1.33 (0.60–2.96)
eGFR 30–60 ml / min 107 / 196 369 / 567 0.76 (0.54–1.05) 1.00 (0.68–1.48)
eGFR < 30 ml / min 42 / 74 69 / 130 1.15 (0.47–2.82) N / A
Cumulated doses of allopurinol (g)
< 200 g 66 / 195 253 / 540 0.68 (0.44–1.04) 0.97 (0.57–1.65)
200–400 g 72 / 97 238 / 307 0.77 (0.42–1.42) 0.62 (0.16–2.31)
 400 g 59 / 49 237 / 216 0.95 (0.52–1.75) 1.25 (0.23–6.83)
Average mg allopurinol per day
(mg)
< 150 mg 51 / 229 235 / 714 0.63 (0.42–0.95) 0.83 (0.51–1.37)
150–250 mg 62 / 79 201 / 231 0.81 (0.43–1.50) 1.30 (0.36–4.67)
 250 mg 84 / 33 290 / 117 0.84 (0.40–1.79) 4.41 (0.83–23.41)
Duration of allopurinol therapy
1–2 years 66 / 137 224 / 360 0.73 (0.46–1.18) 0.88 (0.47–1.66)
 3 years 86 / 122 336 / 461 0.88 (0.60–1.29) 1.16 (0.71–1.91)
*) Adjusted by variables presented in S1 Table.
doi:10.1371/journal.pone.0146172.t002
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Given the well-established link between hyperuricemia and adverse cardiovascular out-
comes, and the extensive literature on beneficial effect of allopurinol on proxies for cardiovas-
cular risk [4,5,7,19], the result may seem surprising. Several counter-hypotheses need to be
considered.
One hypothesis is that the effect on cardiovascular risk is mediated through urate lowering
but this association takes place at higher allopurinol doses than used for gout treatment. This is
supported by evidence suggesting that high doses of allopurinol will result in non competitive
inhibition of xanthine oxidase (the rate-limiting enzyme in purine catabolism) [20], and the
fact that many gout patients are treated with too low doses of allopurinol [21], which also
seems to be the case in this study population with an average allopurinol intake below 140 mg
daily.
Another hypothesis would be that the cardiovascular effect of allopurinol is mediated
through inhibition of xanthine oxidase rather than the lowering of plasma urate. Xanthine oxi-
dase holds important oxidative and antioxidant properties [22]. In pathological conditions,
such as high levels of xanthine, this enzyme produces reactive oxygen species that induces
inflammation and cardiovascular diseases [23]. A very steep dose-response relationship
between allopurinol and cardiovascular diseases without any direct relation to urate level has
been suggested in a study comparing different doses of allopurinol (300 vs. 600 mg / day)
showing an improvement on endothelial function with high doses of allopurinol but not low
doses, placebo or probenecid [7]. The effect of another xanthine oxidase inhibitor (febuxostat)
has in a small study been shown to reduce the arterial stiffness [24]. Unfortunately, other stud-
ies have indicated an increased cardiovascular risk among febuxostat treated compared to allo-
purinol although not statistically significant [25,26].
Finally, our results could be confounded. The use of health care registries means, that we do
not have access to information on some important covariates e.g. smoking. Heavy smoking has
been associated with increased activity of xanthine oxidase [27], but is in part controlled for, by
Table 3. Odds ratios for different exposure definitions of treated-to-target urate levels.
Cases In target /
Not in target
Controls In target /
Not in target
Crude OR
(95% CI)
Adjusted* OR
(95% CI)
Urate threshold for treat-to-target
< 0.20 mmol/l 16 / 522 22 / 1769 2.17 (1.07–4.43) 2.29 (1.05–4.97)
< 0.30 mmol/l 94 / 444 317 / 1474 0.88 (0.66–1.16) 1.11 (0.81–1.52)
< 0.36 mmol/l 197 / 341 728 / 1063 0.77 (0.62–0.95) 1.01 (0.79–1.28)
< 0.42 mmol/l 326 / 212 1231 / 560 0.63 (0.51–0.78) 0.94 (0.73–1.20)
< 0.48 mmol/l 437 / 101 1559 / 232 0.60 (0.46–0.79) 0.88 (0.65–1.20)
Percent change from baseline urate level
0–10 508 / 30 1665 / 126 1.27 (0.83–1.94) 1.24 (0.78–1.98)
> 10 467 / 71 1501 / 290 1.18 (0.88–1.58) 1.22 (0.89–1.68)
> 20 387 / 151 1212 / 579 1.15 (0.91–1.44) 1.07 (0.83–1.38)
> 30 268 / 270 794 / 997 1.10 (0.89–1.35) 1.07 (0.85–1.36)
> 40 160 / 378 398 / 1393 1.32 (1.05–1.66) 1.15 (0.88–1.50)
> 50 71 / 467 153 / 1638 1.57 (1.15–2.16) 1.43 (1.00–2.04)
> 60 30 / 508 47 / 1744 2.17 (1.31–3.61) 1.97 (1.13–3.46)
*) Adjusted by variables presented in S1 Table
doi:10.1371/journal.pone.0146172.t003
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including surrogate markers of smoking in the regression model (e.g. COPD diagnoses and
COPD related prescriptions) and to our knowledge the plasma urate level is not affected by
smoking. Information on dietary factors [28] and alcohol consumptions [29], both known to
alter urate levels were not available either. Some of these factors are also associated with the
metabolic syndrome and increased cholesterol, and might have confounded the results. How-
ever, the effect of such confounding is likely limited, as it is widely appreciated that the
diet alone will not change urate levels sufficiently in gout patients [30]. Another limitation is
the missing information of some intermediate endpoints (e.g. arterial stiffness or coronary cal-
cifications) along the path to develop an APTC outcome. We had prescription data dating back
to 1990. Some of our patients may have used allopurinol before then, and their pre-treatment
duration of hyperuricemia could therefore not be estimated precisely. As it potentially could
affect their pre-treatment cardiovascular risk, this entails a risk of residual confounding. How-
ever, we do not have evidence to support that the duration of hyperuricemia affects the ability
of allopurinol to reach target urate.
These limitations aside, our study has several strengths. It is based on the entire population
in Funen County, with full access to prescription records, admissions, blood samples and
migrations. Virtually all health care related contacts in Denmark is provided by the national
public health authorities and hence included in this study. Thereby, there is little risk of selec-
tion bias in our material. We expect almost complete capture of outcome events. As it is stan-
dard practice to admit all individuals with chest pain or dyspnea along with individuals with
impaired neurology or symptoms of transitory ischemic attacks, it is highly unlikely that we
have missed a substantial number of cases. As for patients who died immediately from the MI
or stroke, the causes of death were ascertained from the Danish register of causes of death.
Given the very high validity of cardiovascular discharge diagnoses in Danish registries
[31,32] there is little risk of misclassification of outcomes. We based our exposure measure on
allopurinol prescriptions and urate measurements and we required the individuals to have
been treated for at least a year. We thus find it unlikely that the patient would redeem multiple
allopurinol prescriptions with patient co-payment without taking the drug. The urate levels
were measured in an accredited laboratory. In all, there is little risk of substantial misclassifica-
tion of exposure.
We have shown that the extensive adjustment is caused by a”little strokes fell great oak”
phenomenon and not by one single covariate, which could have biased the results.
A treat-to-target approach is the mainstay in gout treatment [2,30], but this approach does
not seem to confer a better cardiovascular prognosis than an allopurinol treatment failing to
reach target. We propose that the cardiovascular effect might not be mediated through
urate lowering. At first glance, it may seem as an awkward suggestion, since it is well estab-
lished that hyperuricemia is associated with high cardiovascular risk, that allopurinol
lowers urate levels and that allopurinol improves the cardiovascular risk. However, there are
equivalent examples from other parts of the pharmacotherapeutic literature. E.g., the effect of
statins on cardiovascular risk is not entirely mediated by cholesterol lowering [33–35], and the
effect of ACE-inhibitors on stroke risk is not entirely explained by lowering of blood pressure
[36].
It is important to emphasize that our results do not contradict that allopurinol is effective
in preventing cardiovascular event. Our result is fully compatible with a dose dependent
effect of allopurinol, but for a given dose of allopurinol the effect on urate level is not
important for achieving the cardiovascular effect. Future studies will establish the role of allo-
purinol in cardiovascular prophylaxis and in particular, the nature of its dose-response
relationship.
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